HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. - Wikidata - wikimedia - TriplyDB

HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.

HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.

http://www.wikidata.org/entity/Q37038068

about

Cixutumumab Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy EGFR/HER-targeted therapeutics in ovarian cancer The insulin-like growth factor system in cancer Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma Where now for anti-EGF receptor therapies in colorectal cancer?Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors.Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer.Establishment of platform for screening insulin-like growth factor-1 receptor inhibitors and evaluation of novel inhibitors.Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse.ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis.The proliferating role of insulin and insulin-like growth factors in cancer.Can we unlock the potential of IGF-1R inhibition in cancer therapy?Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924 A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors.Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines.IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors.Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.Insulin activates EGFR by stimulating its interaction with IGF-1R in low-EGFR-expressing TNBC cells.Quantifying insulin receptor isoform expression in FFPE breast tumors Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad?Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors Complement component 1, q subcomponent binding protein is a marker for proliferation in breast cancer.XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer.IGF-1 receptor inhibitors in clinical trials--early lessons Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth.Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).

P2860

Q24609058-E8A35FC6-889B-44FE-B4D0-5985F78104C8 Q26764879-871348CC-E66C-4D0F-BA07-9A9D1EF5CAC1 Q26824462-EC28DAFE-D207-4F9C-AEB1-EF7BE9845D14 Q26863231-F8658EDA-02C4-4E9F-9B06-00FDF2443344 Q27013945-184C3A14-40EB-4A68-8B2E-7D9DFF64CA34 Q28088432-07DCBE13-3EE5-4410-A9C3-C3DBCCE47E8D Q30395770-696BC2D9-30BF-4361-BB55-591654F665C4 Q30411769-AF7E385A-93B0-4EFD-9D77-9FE490FCA9A8 Q31038305-B4522D21-842E-46BB-9F25-4C2921242465 Q33395016-BD4F7A35-16DC-44A8-B1A8-B9F5184498E5 Q33406979-E06F7EA6-4CEB-4DCB-AC8D-A9BB3B0ECFAA Q33581021-2977D715-4A0C-4061-BACF-AC79075EF206 Q33846405-A3453BB8-B3A4-410A-987B-4B2015199DF5 Q33921296-4F167CB7-EFC3-4F23-BB7F-7A1AA096A8D4 Q33923364-0CB9C195-FDA2-4170-9164-AF62F05BD456 Q33979359-EA9FA858-586D-4C25-A26A-DEE36AB0F5F0 Q34133760-2251C44D-2B3C-4044-A782-1D09A9347E52 Q34172625-A3582D99-425B-4D44-B315-CB246625B4DC Q34336988-95ABA442-5463-420C-9FF0-4A89891CBD9E Q34674256-F2477EC0-A639-40BE-9EB0-80B950AB85BF Q35146077-B7455ADD-5D7F-499E-BFD8-74781F30C8BD Q35201923-EDDB4CE5-17C8-484B-80EC-29808FB25FF7 Q35494483-F60DC136-BF1F-46EE-8BFB-39AB328F681B Q35592388-1DEC4938-851B-4D39-B7FE-69F63F921226 Q35683561-D3DA7FF7-4781-449F-9F17-438BF6ECC754 Q35836632-D4CF19E9-94D2-4290-994B-37CE50990B3B Q35989684-2F9D54D4-BCF3-4C37-BF2C-BF4F690BE4D5 Q36051560-C3B84F83-0A74-4DBA-8436-E0559496C54B Q36082594-1F4927EE-964A-42AA-AE39-4F9302F2E9FA Q36084201-0829F4E3-1215-4422-A277-B03E2BBA312F Q36169793-5FB82CFE-9BAF-4DDC-BCCB-77636B179721 Q36357195-84F5FE7E-C293-46BB-9476-A0451C9F8E3C Q36387216-E453B64F-4AB5-4A44-8B8D-DAEB9CA68B84 Q36673960-50BA0C91-DDE0-4B2D-A1A3-CAB9229144B7 Q37071560-C741743A-E304-4664-B9E8-9E98EF64ECE9 Q37138970-A8D5A998-288F-4FE7-8384-F2CACE4D9D6E Q37304764-2E7D028D-B06B-49D2-89C8-D783B584F1A1 Q37309022-FF01D44F-3EA6-4459-A2AA-2E9671089BC0 Q37430771-2FCA34E9-FF28-4484-954E-EBC336BFB400 Q37565213-137A634A-71F5-45C6-B620-185E6CAEBAA4

P2860

HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.

http://www.wikidata.org/entity/Q37038068

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 September 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

HER receptor signaling confers ...... eceptor inhibitor, BMS-536924.

@en

HER receptor signaling confers ...... eceptor inhibitor, BMS-536924.

@nl

type

label

HER receptor signaling confers ...... eceptor inhibitor, BMS-536924.

@en

HER receptor signaling confers ...... eceptor inhibitor, BMS-536924.

@nl

prefLabel

HER receptor signaling confers ...... eceptor inhibitor, BMS-536924.

@en

HER receptor signaling confers ...... eceptor inhibitor, BMS-536924.

@nl

P1433

Q37038068-F5F57C66-4DAE-4DAD-A5A8-ADDD7CB9E8F4

P1476

Q37038068-3E86C312-6CF9-465C-B223-2F827B7D7D18

P2093

Q37038068-11C32696-6D4B-4896-88AC-08DD8E0766DD

Q37038068-18E453EE-D948-492B-A23D-CB1837D7B15E

Q37038068-4E6D7C27-1939-454E-8C06-5A8320CE969D

Q37038068-66B1F4C8-E1F1-4583-8380-3CFD49596DC7

Q37038068-8B517ADE-729C-4A9C-ADD3-05EE010A26B8

Q37038068-A5F2EFFF-4FD0-4B47-B466-226FF2CE3C00

Q37038068-A96DA1BB-0A29-4A97-88CA-A2356CE07E52

Q37038068-AE4DB9FD-594F-4F84-8794-E78744CDFAB9

Q37038068-B312F6B0-0946-4D7A-B9CF-B4A1FC55E795

Q37038068-C959AE28-2192-4F5A-9BE0-7077AEC9DFC5

P2860

Q37038068-0A933053-9D42-4676-A373-F74A9F3B65F3

Q37038068-0FB19C7E-FA81-4CD1-9B15-C2754F5018FD

Q37038068-16CA8883-7A7F-4DAF-AD1C-B00BE608077F

Q37038068-185FFE08-416F-4597-B8EC-CF33A6C11464

Q37038068-19584EF3-2DBB-4511-9872-A61B84E24258

Q37038068-24A5EEAF-F819-4079-A3B6-B7E31E1B258A

Q37038068-266028ED-53B2-4E2A-8718-EE4A01A1C21F

Q37038068-27065D0D-53D2-4D8E-B8CC-E30788573615

Q37038068-281EC459-8DFC-4BF3-90DC-B25D5EC53EB4

Q37038068-33373F9C-7859-4E63-AB81-9BB69DA16201

P304

Q37038068-D5C7BB4D-81F6-42E4-936E-5B4320836ED3

P31

Q37038068-72B02D3F-A848-4676-91BD-9AAF10335D08

P356

Q37038068-E0F0DFD7-B486-456E-B42B-944AD968D89A

P433

Q37038068-9D0FC2EA-EFC2-4EE9-BC11-7700A8F1E20F

P478

Q37038068-DB177BBB-50FC-4B69-94B9-7204D21F362B

P577

Q37038068-774B1202-4206-4361-B2BA-E6EB3DCEB855

P698

Q37038068-EABECA7F-F972-46AD-A280-F8934FAD9CDE

P921

Q37038068-0EA1CADE-0BAE-4D23-899B-B2BAE1B54758

P932

Q37038068-B0F9F688-0C28-4576-BF6D-61EE4A49DF58

P356

1535-7163.MCT-08-0493

P1433

Molecular Cancer Therapeutics

P1476

HER receptor signaling confers ...... eceptor inhibitor, BMS-536924.

@en

P2093

Charles Erlichman

http://www.w3.org/2001/XMLSchema#string

Chunrong Yu

http://www.w3.org/2001/XMLSchema#string

Cynthia TenEyck

http://www.w3.org/2001/XMLSchema#string

Joan M Carboni

http://www.w3.org/2001/XMLSchema#string

Malvika Sagar

http://www.w3.org/2001/XMLSchema#string

Marco M Gottardis

http://www.w3.org/2001/XMLSchema#string

Paul Haluska

http://www.w3.org/2001/XMLSchema#string

Ricardo M Attar

http://www.w3.org/2001/XMLSchema#string

Tai W Wong

http://www.w3.org/2001/XMLSchema#string

Xiaonan Hou

http://www.w3.org/2001/XMLSchema#string

P2860

Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

The deaf and the dumb: the biology of ErbB-2 and ErbB-3

Cellular actions of the insulin-like growth factor binding proteins

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

EGFR antagonists in cancer treatment

The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.

Insulin-like growth factor-I decreased etoposide-induced apoptosis in glioma cells by increasing bcl-2 expression and decreasing CPP32 activity.

P304

2589-2598

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-08-0493

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18765823

http://www.w3.org/2001/XMLSchema#string

P921

P932

2614316

http://www.w3.org/2001/XMLSchema#string